中国生物制药公告集团与勃林格殷格翰在中国大陆联合推广的宗艾替尼片（商品名：圣赫途）已获得中国国家药品监督管理局的上市批

智通财经08-29

中国生物制药公告集团与勃林格殷格翰在中国大陆联合推广的宗艾替尼片（商品名：圣赫途）已获得中国国家药品监督管理局的上市批准用于治疗存在HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。圣赫途是全球首个且目前唯一的口服HER2酪氨酸激酶抑制剂此次在中国获得附条件批准是基于Beamion-LUNG 1研究的积极结果该试验评估了...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2563017506?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-29 16:33","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2563017506","market":"hk","top_or_hot":-1,"title":"中国生物制药公告集团与勃林格殷格翰在中国大陆联合推广的宗艾替尼片（商品名：圣赫途 ）已获得中国国家药品监督管理局的上市批","media":"智通财经","content":"<div>\n<p>中国生物制药公告集团与勃林格殷格翰在中国大陆联合推广的宗艾替尼片（商品名：圣赫途 ）已获得中国国家药品监督管理局的上市批准用于治疗存在HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。圣赫途 是全球首个且目前唯一的口服HER2酪氨酸激酶抑制剂此次在中国获得附条件批准是基于Beamion-LUNG 1研究的积极结果该试验评估了...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国生物制药公告集团与勃林格殷格翰在中国大陆联合推广的宗艾替尼片（商品名：圣赫途 ）已获得中国国家药品监督管理局的上市批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国生物制药公告集团与勃林格殷格翰在中国大陆联合推广的宗艾替尼片（商品名：圣赫途 ）已获得中国国家药品监督管理局的上市批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-29 16:33 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中国生物制药公告集团与勃林格殷格翰在中国大陆联合推广的宗艾替尼片（商品名：圣赫途 ）已获得中国国家药品监督管理局的上市批准用于治疗存在HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。圣赫途 是全球首个且目前唯一的口服HER2酪氨酸激酶抑制剂此次在中国获得附条件批准是基于Beamion-LUNG 1研究的积极结果该试验评估了...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ08YS42.EUR","symbol_name":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2563017506","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563017506","pubTimestamp":1756456419,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"中国生物制药公告集团与勃林格殷格翰在中国大陆联合推广的宗艾替尼片（商品名：圣赫途 ）已获得中国国家药品监督管理局的上市批准用于治疗存在HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","01177":"中国生物制药","BK1589":"北水核心资产","BK1191":"制药","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LUNG":"Pulmonx Corp","BK1521":"挪威政府全球养老基金持仓","BK4198":"医疗保健用品","BK1515":"抗疫概念","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK4082":"医疗保健设备"},"translate_title":"Zongaitinib tablets (trade name: Shenghetu) jointly promoted by China National Biopharmaceutical Announcement Group and Boehringer Ingelheim in mainland China have been approved by the National Medical Products Administration of China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1,"LUNG":1},"content_text":"中国生物制药公告集团与勃林格殷格翰在中国大陆联合推广的宗艾替尼片（商品名：圣赫途 ）已获得中国国家药品监督管理局的上市批准用于治疗存在HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。圣赫途 是全球首个且目前唯一的口服HER2酪氨酸激酶抑制剂此次在中国获得附条件批准是基于Beamion-LUNG 1研究的积极结果该试验评估了宗艾替尼在HER2（ERBB2）突变晚期NSCLC患者中的疗效和安全性。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2563017506","isCrawlerRequest":true}

中国生物制药公告集团与勃林格殷格翰在中国大陆联合推广的宗艾替尼片（商品名：圣赫途 ）已获得中国国家药品监督管理局的上市批

精彩评论

中国生物制药公告集团与勃林格殷格翰在中国大陆联合推广的宗艾替尼片（商品名：圣赫途）已获得中国国家药品监督管理局的上市批